Inflection Biosciences co-founder Dr Michael O’Neill, chief executive Darren Cunningham and Prof Bryan Hennessy, senior clinical lecturer at the Royal College of Surgeons. Photograph: Julien Behal

Irish drug development company Inflection Biosciences has signed a global deal for their leading cancer medicine candidate. Its therapy aims to shut (...)

The collaboration between Inflection Biosciences and the University of Texas Cancer Center  aims to explore the effects of the company’s pipeline of potential cancer treatments in head and neck cancer.

Dublin drug development company Inflection Biosciences has signed a research deal with the University of Texas Cancer Center (MD Anderson). The start(...)

Punchestown Racecourse has invested €4 million in a new stand that it plans to open on the first day of its annual festival next week.

Builders are warning of a looming skills shortage as new figures show their industry continues to expand on the back of the Republic’s housing squeeze(...)

Immunotherapies have been a major focus of cancer research in recent years

Dublin drug development company Inflection Biosciences has signed a research deal with Trinity College. The start-up is working on a new approach to b(...)

Dr Michael O’Neill, director of research and development at Inflection Biosciences, Darren Cunningham, chief executive at Inflection and Prof Bryan Hennessy, senior clinical lecturer at RCSI and consultant medical oncologist. Photograph: Julien Behal

Irish drug development company Inflection Biosciences will present data on its fledgling breakthrough breast cancer therapy to the American Associatio(...)